Provided by Tiger Fintech (Singapore) Pte. Ltd.

Larimar Therapeutics, Inc.

2.33
-0.0400-1.69%
Post-market: 2.330.00000.00%16:05 EDT
Volume:628.54K
Turnover:1.46M
Market Cap:149.18M
PE:-1.77
High:2.37
Open:2.33
Low:2.27
Close:2.37
Loading ...
Sep 29, 2020

Major Issues Report

8-K - Current report
Aug 31, 2020

Correspondence

CORRESP [Cover] - Correspondence
Aug 14, 2020

Major Issues Report

8-K/A [Amend] - Current report
Aug 14, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 11, 2020

Major Issues Report

8-K - Current report
Aug 06, 2020

Major Issues Report

8-K - Current report
Jul 13, 2020

Correspondence

CORRESP [Cover] - Correspondence
Jul 01, 2020

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jun 30, 2020

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Jun 26, 2020

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Jun 26, 2020

Major Issues Report

8-K/A [Amend] - Current report
Jun 11, 2020

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Jun 08, 2020

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Jun 08, 2020

Beneficial Ownership Change

SC 13D - General statement of acquisition of beneficial ownership
Jun 05, 2020

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jun 03, 2020

Major Issues Report

8-K - Current report
Jun 02, 2020

Major Issues Report

8-K - Current report
May 07, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 27, 2020

Correspondence

CORRESP [Cover] - Correspondence
Apr 24, 2020

Major Issues Report

8-K - Current report